DBVT

DBV Technologies
CAPPED RATING

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies (DBVT) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -2.1
Rev Growth YoY -53.3%
Gross Margin N/M
Price Return 3M -29.6%
Price Return 12M 52.3%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 161.1
ROE -142.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) D+ (1.6) C+ (2.7) C (2.4) C- (1.9) C (2.3)
2026-08-04 C+ (2.7) D+ (1.6) C+ (2.7) C (2.4) C- (1.9) C (2.3)
2026-08-03 C+ (2.7) C- (2.1) C+ (2.6) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C- (2.1) C+ (2.6) C (2.4) C- (1.9) C (2.4)